Of the Biotech Sector’s Selloff
Testing the lows in biotech firms’ stock prices is nothing but testing the biotech investors’ degree of vulnerability to fear. Fear leads many biotech investors to hysterically sell their stocks just by hearing negative stories about the sector. The stock selloff continues even when the frightening fabricated stories happen not to make sense that convince mature people to believe them.
A Quick Reminder
Spark Therapeutics (ONCE) is a gene therapy firm that aim at developing one . . .
This content is for paid subscribers.
Today’s Highlights January 12, 2016